[{"Assets_0_Q1_USD":34700000.0,"CommonStockSharesOutstanding_0_Q1_shares":38649237.0,"EarningsPerShareBasic_1_Q1_USD":-0.14,"EarningsPerShareDiluted_1_Q1_USD":-0.14,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-4500000.0,"NetIncomeLoss_1_Q1_USD":-5300000.0,"StockholdersEquity_0_Q1_USD":13900000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":38649237.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":38649237.0,"Ticker":"VXRT","CIK":"72444","name":"AVIRAGEN THERAPEUTICS, INC.","OfficialName":"Vaxart Inc Common Stock","form":"10-Q","period":"20170930","fy":"2018.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"564888665.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20171107"}]